ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

摘要:

Abstract: We evaluated the effect of transdermal norethisterone acetate (NETA) versus oral medroxyprogesterone acetate (MPA) on the lipids of 28 postmenopausal women taking hormonal replacement therapy for climacteric symptoms. All the 28 patients were using conventional patches releasing 0.050 mg of estradiol per day continuously. However, while one group of 14 patients received transdermal NETA (0.25 mg/day) for 14 days of the cycle, the other group of 14 patients received oral MPA (10 mg/day) for the same number of days. The patients were randomly allocated to one of the two groups. The treatment cycles were repeated for 12 months. There was no significant difference between the two treatment groups for compliance and for incidence of side effects. Both hormonal replacement therapies were equally effective in relieving climacteric symptoms. All the patients underwent serum lipid assays twice, the first time before starting treatment and then again during the progestogen phase of the 12th and last cycle. Serum total cholesterol (TC), low-density lipoprotein (LDL-C), and triglyceride levels did not change significantly during both treatments. Transdermal estradiol associated with oral MPA significantly reduced high-density lipoprotein (HDL-C) by 17.9% (p < 0.05) and significantly increased LDL-C/HDL-C and TC/HDL-C risk ratios by 61.7% (p < 0.05) and 33.1% (p < 0.05), respectively. In contrast, administration of the transdermal NETA did not significantly affect HDL-C levels (– 1.9% of decrease) and, consequently, the risk ratios were minimally altered, with 3.3 and 6.0% increases for TC/HDL-C and LDL-C/HDL-C, respectively. There was a statistically significant difference (p < 0.05) in HDL-C net changes between MPA and NETA treatments (+ 8.5 and - 8.0 mg/dl, respectively). We can therefore conclude that the association of transdermal NETA with transdermal estradiol elicits a relatively benign impact on lipoprotein profile in comparison to oral MPA association

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

摘要:

Abstract: To test the hypothesis that estrogen replacement therapy preserves skin thickness, and to determine the relationship between bone mass and skin thickness, we performed a cross-sectional analysis of baseline data collected for a multicenter prospective study of osteoporotic fractures. 1,072 ambulatory nonblack women aged 65 years or older were recruited from population-based listings at two US clinical centers. Demographic and historical information and anthropometric measurements were obtained from a baseline questionnaire, interview, and examination. Estrogen use was assessed by questionnaire and interview. Skin thickness was measured over the middle metacarpophalangeal joint with mechanical calipers. Bone mass was measured by single photon absorptiometry at three appendicular sites: the distal and midradius, and the calcaneus. After adjusting for other potential confounding factors, each 10 years of age was associated with an 8.6% reduction in skin thickness, and every 5-kg/m2increase in body mass index was associated with a 3.8% increase in skin thickness. Smokers had thinner skin than nonsmokers. Estrogen users had thinner skin; compared to never-users, current users had a 5.1% reduction in skin thickness, and past users had a 2.0% reduction in skin thickness. Among estrogen users, every 10 years of use was associated with a 1.7% reduction in skin thickness. Skin thickness was weakly associated with bone mass of the middle radius and calcaneus, but not the distal radius. We found no evidence that estrogen preserves skin thickness; indeed, estrogen use is associated with thinner skin. Although skin thickness and bone mass are related, the association is too weak to be useful for predicting bone mass

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

摘要:

Abstract: Forty-eight women in natural or surgical menopause, who attended a menopausal-gynecological clinic, were examined before starting any treatment by a psychiatrist using the General Health Questionnaire-28 and the Hamilton scales for anxiety and depression, to measure the degree of their psychological distress. This degree was relatively high, especially for women in surgical menopause. After 6 months, in which 36 of the attendees received hormone replacement therapy, the psychiatric assessment was repeated and much lower levels of distress were found, so that in no case was psychiatric treatment needed. This improvement in psychological state could perhaps partly be attributed to the attention of the special setting, but is probably a result of the hormone replacement therapy

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID

ISSN:1072-3714    

出版商:OVID    

年代:1994

数据来源: OVID